Herzich Paul 4

What Happened

• Paul Herzich, Chief Technology Officer of Solid Biosciences (SLDB), had 7,187 restricted stock units (RSUs) convert to common shares on 2026-02-13. Those RSUs vested and converted with no cash exercise price.
• Following the vesting, 3,616 shares were sold in the open market on 2026-02-18 at a weighted average price of $5.82, generating approximately $21,057. The sale was a sell-to-cover to satisfy withholding taxes and was not a discretionary trade.

Key Details

• Transaction dates: RSU conversion (vest) on 2026-02-13; open-market sale on 2026-02-18.
• Sale price: weighted average $5.82; reported sale prices ranged from $5.23 to $6.14.
• Shares involved: 7,187 RSUs converted; 3,616 shares sold to cover taxes.
• Shares owned after the transactions: not disclosed in this Form 4.
• Notable footnotes: RSUs represent contingent rights to one share each (F1); sale was automatic sell-to-cover per durable instruction adopted Aug 16, 2024 (F2); RSUs granted Feb 13, 2024 vest 25% annually over four years (F4).
• Filing timing: Form 4 filed 2026-02-18 reporting the 2/13 vesting and the 2/18 sale. The 2/13 conversion was reported five days later and may be outside the standard two-business-day reporting window.

Context

• This was a conversion of vested RSUs (derivative conversion) followed by an automatic sell-to-cover to pay withholding—common and typically routine for executives when equity awards vest.
• The transactions do not indicate a discretionary sell motivated by company outlook; they relate to tax withholding. Purchases generally carry more signal for bullish insider sentiment than routine sell-to-cover transactions.